CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration.
CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration.
复制标题
DOI：
10.1007/s12177-010-9055-1
复制
发表时间：
2010-06-01
期刊：
影响因子：
--
通讯作者：
Yoneya, Shin
中科院分区：
文献类型：
--
作者：
Imai, Daisuke;Mori, Keisuke;Yoneya, Shin
我们确定补体因子H （CFH）、高温要求a -1 （HTRA1）、血管内皮生长因子（VEGF）和色素上皮衍生因子（PEDF）基因型与单次玻璃体内注射贝伐单抗治疗老年性黄斑变性（AMD）的反应之间是否存在关联。83例接受贝伐单抗注射治疗的渗出性AMD患者采用TaqMan方法对CFH基因的3个单核苷酸多态性（snp; rs800292、rs1061170、rs1410996）、HTRA1基因的1个rs11200638-SNP、VEGF基因的3个snp （rs699947、rs1570360、rs2010963）和PEDF基因的4个snp （rs12150053、rs12948385、rs9913583、rs1136287）进行基因分型。CFH-rs1061170的CT基因型（杂合子）在1个月和3个月的视力无应答者中比TT基因型（非危险等位基因纯合子）更常见，而我们的研究队列中没有CC基因型（危险等位基因纯合子）（p分别为7.66*10（-3）和7.83*10(-3)）。VEGF-rs699947和PEDF-rs1136287也与1个月时的视力变化相关（p分别为5.11*10（-3）和2.05*10(-2)）。这些变异可能被用作遗传生物标志物，以评估黄斑变性患者对玻璃体内贝伐单抗治疗反应的视力结果。
We determined whether there is an association between complement factor H (CFH), high-temperature requirement A-1 (HTRA1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor (PEDF) genotypes and the response to treatment with a single intravitreous injection of bevacizumab for age-related macular degeneration (AMD). Eighty-three patients with exudative AMD treated by bevacizumab injection were genotyped for three single nucleotide polymorphisms (SNPs; rs800292, rs1061170, rs1410996) in the CFH gene, a rs11200638-SNP in the HTRA1 gene, three SNPs (rs699947, rs1570360, rs2010963) in the VEGF gene, and four SNPs (rs12150053, rs12948385, rs9913583, rs1136287) in the PEDF gene using a TaqMan assay. The CT genotype (heterozygous) of CFH-rs1061170 was more frequently represented in nonresponders in vision than TT genotypes (nonrisk allele homozygous) at the time points of 1 and 3months, while there was no CC genotype (risk allele homozygous) in our study cohort (p=7.66*10(-3), 7.83*10(-3), respectively). VEGF-rs699947 was also associated with vision changes at 1month and PEDF-rs1136287 at 3months (p=5.11*10(-3), 2.05*10(-2), respectively). These variants may be utilized for genetic biomarkers to estimate visual outcomes in the response to intravitreal bevacizumab treatment for AMD.